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Background: The loss of 5-hydroxymethylcytosine (5hmC) has been identified as a novel epigenetic hallmark for
melanoma. One of the known mechanisms underlying the loss of 5hmC is the decrease in expression of ten-eleven
translocation family dioxygenase (TET) genes, which encode enzymes that catalyze the generation of 5hmC. Overexpressing
TET2 was shown to partially reestablish a normal 5hmC profile in melanoma and decrease invasiveness in rodents.
However, the feasibility to overexpress TETs in patients remains unclear. We and others have recently demonstrated
that TETs require vitamin C as a cofactor to generate 5hmC. This finding prompted us to test whether vitamin C, as
an alternative to overexpressing TETs, could rebuild 5hmC content in melanoma.
Results: Consistent with previous reports, we found that the expression of TETs was decreased in various melanoma
cell lines. In contrast, the expressions of sodium-dependent vitamin C transporters (SVCTs) were down-regulated in cell
lines derived from melanoma metastases. Treatment of vitamin C at the physiological level (0.1 mM) promoted the
content of 5hmC in melanoma cell lines derived from different stages toward the level of healthy melanocytes, which
was comparable to the effect of overexpressing TET2. Vitamin C treatment decreased the malignancy of metastatic
A2058 cells by inhibiting migration and anchorage-independent growth, while not exerting any effect on the rate
of proliferation. Further, vitamin C treatment caused alterations in genome-wide transcriptions shown by RNA-seq,
predominantly in ArhGAP30 and genes involved in extracellular matrix remodeling, which could underlie the decreased
malignant phenotypes.
Conclusions: Our data support the idea that vitamin C treatment increases 5hmC content in melanoma cells, while
causing a decrease in tumor-cell invasiveness and clonogenic growth in soft agar. Thus, vitamin C could be a potential
epigenetic treatment for melanoma.
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Aberrant epigenetic alterations, along with genetic muta-
tions, are known to contribute to the onset of cancer.
Recently, the loss of 5-hydroxymethylcytosine (5hmC)
has been identified as a novel hallmark for most, if not
all, types of cancer (including melanoma) [1-4]. The con-
tent of 5hmC is relatively high in healthy melanocytes
but is gradually lost during the progression from benign* Correspondence: zliu@med.miami.edu; gwang@med.miami.edu
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unless otherwise stated.nevi through advancing stages of primary and metastatic
melanoma [3]. 5hmC is converted from 5-methylcytosine
(5mC), the major epigenetic modification of mammalian
DNA, by a group of enzymes termed TET (ten-eleven
translocation) family dioxygenases [5,6]. TETs can further
oxidize 5hmC to 5-formylcytosine and 5-carboxylcytosine,
which are eventually replaced by unmodified cytosine thus
completing the process of demethylation. The cascade
oxidation of 5mC by TETs and the ensuing base excision
repair has been recognized as the most consistent mech-
anism underlying the active demethylation of DNA [7].
The loss of 5hmC demonstrates an epigenetic drift in
the dynamics of DNA methylation-demethylation, which
could potentially be involved in the pathogenesis of mel-
anoma. Interestingly, 5hmC is relatively stable and isral. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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ther, 5hmC recruits different sets of binding proteins, as
compared to 5mC, and correlates with unique transcrip-
tion profiles [10-12]. In addition to being a DNA demeth-
ylation intermediate, 5hmC serves as an epigenetic mark
with unique regulatory capabilities. Therefore, the global
loss of 5hmC can change genome stability and genome-
wide transcription patterns, which ultimately leads to a
cascade of phenotypic transformations from healthy mela-
nocytes toward malignant melanoma.
One of the known mechanisms underlying the loss of
5hmC in melanoma is a lower expression of the TET
and isocitrate dehydrogenases (IDH) genes [3,4], which
encode enzymes that catalyze the production of 2-
oxoglutarate, a co-substrate for the TET enzymes. It has
been shown that overexpressing TET2 could partially re-
establish a normal 5hmC profile in cultured melanoma
cells and decrease their invasiveness in modeled animals
[3]. These findings suggest that rebuilding the 5hmC con-
tent can be a potential treatment for melanoma. However,
the feasibility to clinically overexpress TETs or IDHs in
patients suffering from melanoma remains unclear.
TETs belong to the iron and 2-oxoglutarate-dependent
dioxygenase superfamily. These dioxygenases utilize Fe2+
as a cofactor, 2-oxoglutarate as a co-substrate, and some
of them require vitamin C (ascorbate) as an additional
cofactor to achieve full catalytic activity. We and other
groups have recently shown that vitamin C induces the
generation of 5hmC, most likely by acting as a cofactor
for TET dioxygenases to hydroxylate 5mC. Vitamin C at
physiological levels has been shown to increase the glo-
bal content of 5hmC in vivo and in vitro [13-17]. This
previously unknown function of vitamin C in modulat-
ing DNA demethylation prompted us to test whether
vitamin C, as an alternative to overexpressing TETs or
IDHs, could be a potential epigenetic treatment for mel-
anoma by rebuilding 5hmC profiles.
Results
The expression of TETs was decreased in melanoma cell
lines
We first evaluated the expression level of TETs (TET1,
TET2, and TET3) in primary cultured healthy human
melanocyte lines (FOM-113) and various melanoma cell
lines using qRT-PCR. These melanoma cell lines include
those that are derived from the radial growth phase
(RGP, SBcl2 and WM35), vertical growth phase (VGP,
WM278 and WM3248) and metastatic stage (C8161,
A2058). Consistent with a previous report [3], we found
that the expression of TET1 and TET2 was consistently
decreased in all melanoma cell lines examined, as com-
pared to the normal melanocyte line (Figure 1A). TET3
was not detectable by qRT-PCR in our lab. Of the cell
lines evaluated, the lowest expression level of both TET1and TET2 was observed in two metastatic melanoma
cell lines.
The expression of SVCT2 was decreased in metastatic
melanoma cell lines
The uptake and accumulation of vitamin C by cells are
mainly via sodium-dependent vitamin C transporters
(SVCT). There are two types of SVCTs, which are,
SVCT1 and SVCT2. We then measured the expression
of SVCT1 and SVCT2 in the same melanoma cell-line
panel used for the evaluation of TETs. Both SVCT1 and
SVCT2 were detectable in these cell lines by qRT-PCR,
although the expression level of SVCT1 is much lower
than that of SVCT2 (approximately 3 cycles in differ-
ence). The mRNA levels of SVCT1 and SVCT2 were ei-
ther decreased or increased in the examined melanoma
cell lines compared to the normal melanocytes. How-
ever, only in those metastatic melanoma cell lines
(C8161 and A2058), the expression of both SVCT1 and
SVCT2 was consistently decreased, as compared to the
healthy melanocytes (Figure 1B). Interestingly, it has
been shown that the uptake rate of ascorbate (the dom-
inant form of vitamin C in the plasma) by melanoma
cells (SK-MEL-131) is only approximately 50% of the up-
take rate by healthy melanocytes [18]. A decreased ex-
pression of SVCTs presumably could also result in a
lower efficiency in vitamin C uptake in these metastatic
melanoma cell lines. These results suggest that a local
vitamin C deficiency, along with a decreased level of
TETs, may contribute to the global loss of 5hmC in
metastatic melanoma cells.
Vitamin C treatment promoted 5hmC content in melanoma
cells toward that of healthy melanocytes
Next, we tested whether vitamin C treatment could in-
crease the global content of 5hmC in melanoma cells.
The content of 5hmC was relatively high in healthy me-
lanocytes (FOM-113) but was barely detectable by dot-
blot assay in SBcl-2 (RGP), WM278 (VGP), and A2058
(metastasis) melanoma cells cultured in a vitamin C-free
medium. These cell lines were chosen based on their de-
creased expression of both SVCT1 and SVCT2. The
average concentration of vitamin C in the plasma of
humans is at approximately 0.05 mM range and could
reach concentrations of up to approximately 0.15 mM
[19]. We reasoned that a relatively higher concentration of
vitamin C, but still in the range of physiological concen-
tration, could compensate for the down-regulated SVCTs
in melanoma cells. In this case, vitamin C at 0.1 mM was
chosen for treatment. There was no obvious change in the
content of 5hmC in healthy melanocytes after treatment
with vitamin C (0.1 mM) for 48 h, which could be ex-
plained by the possible saturation of dot-blot signals. In
contrast, vitamin C treatment dramatically increased the
Figure 1 The relative transcription levels of TETs and SVCTs in melanoma cells. Levels of TETs and SVCTs (mean) in a healthy melanocyte line are
set up as ‘1’. (A) The mRNA levels of TET1 and TET2, measured by qRT-PCR, are decreased in melanoma cell lines derived from RGP, VGP, and metastatic
stages compared to a healthy melanocyte line FOM-113. (B) The mRNA levels of SVCTs are either decreased or increased in the examined melanoma cell
lines. Comparatively, the transcription levels of both SVCTs are decreased in the melanoma cell lines (C8161, A2058) derived from the metastatic stage.
(Mean ± SD, *P < 0.05).
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the level in healthy melanocytes (Figure 2). After treat-
ment with vitamin C, the content of 5hmC in WM278
cells and A2058 cells was increased to approximately 80%
of control melanocytes, while the content of 5hmC in
SBcl-2 cells was only increased to approximately 50% of
control melanocytes. It remains unknown to us why the
response of SBcl-2 cells was less than the other cell lines,
though the expression of TETs and SVCTs in SBcl-2 cells
of RGP was at similar levels as the other melanoma cell
lines. Nevertheless, these results suggest that vitamin C at
physiological levels indeed promotes the content of 5hmC
toward the level of healthy melanocytes, which is compar-
able to the effect of overexpressing TET2, as shown previ-
ously [3].Vitamin C time-dependently increased 5hmC content in
A2058 cells
Previous studies have implicated a potential pharmaco-
logical effect of elevating vitamin C to higher concentra-
tions in the plasma (>0.3 mM) on certain types of
cancer [20]. Pharmacological levels of vitamin C in the
plasma can only be achieved through intravenous injec-
tions. Although intravenous injections in a certain way
may complicate the delivery of vitamin C to patients, we
still tested whether vitamin C at pharmacological levels
has an even stronger effect on 5hmC generation in mel-
anoma cells. The A2058 cell line was used as a cell
model in the first published study on 5hmC reestablish-
ment in melanoma. Following this, we chose the A2058
cell line as a model also considering their decreased
Figure 2 Vitamin C treatment raises 5hmC content toward that in healthy melanocytes. (A) The dot blot shows vitamin C treatment (0.1 mM) for
48 h and increases the global content of 5hmC in melanoma cells at different stages (RGP, VGP, and metastatic) toward the level in healthy melanocytes.
(B) The semi-quantitative analysis of the dot-blot indicates that vitamin C significantly promotes 5hmC generation in melanoma cells. (Mean± SD, *P< 0.01).
The level of 5hmC (mean) in untreated melanocytes is set up as ‘1’. The relative levels of 5hmC in melanoma cells with or without vitamin C treatment
are shown.
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5hmC signal was barely detectable in A2058 cells when
cultured without vitamin C. After supplementation of
vitamin C (0.01 mM) in the medium for 24 h, we found that
the content of 5hmC increased about sixfold, and 0.1 mM
vitamin C induced further increase in 5hmC (nearlyFigure 3 Vitamin C treatment increases the content of 5hmC in A2058 melanom
show that treatment with vitamin C (0.01 mM) increase 5hmC to approximate
to 1 mM) induce 5hmC generation at a similar level (approximately ninefold
increases the content of 5hmC in A2058 cells as showed by the dot-blot an
relative amounts of 5hmC.ninefold), as compared to the basal level (Figure 3A & B).
However, 5hmC was induced to a similar level (P > 0.05) in
response to vitamin C treatment, regardless of how low
(0.1 mM) or high (0.5 mM and 1 mM) the concentrations
were. This suggests that vitamin C at pharmacological levels
does not incur greater benefits in promoting 5hmCa cells. (A to B) The dot-blot and semi-quantitative analysis of the dot-blot
ly sixfold of the basal level. Higher concentrations of vitamin C (0.1 mM
in increase). (C to D) Vitamin C treatment (0.1 mM) time-dependently
d the semi-quantitative analysis of the dot-blot. Quantitative data are
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physiological levels.
Similar to what we previously observed in non-malignant
cells [13], vitamin C treatment also enhanced the gener-
ation of 5hmC in A2058 cells in a time-dependent manner.
The 5hmC content was increased approximately threefold
in 6 h, approximately eightfold in 24 h, and approximately
ninefold in a 48-h post vitamin C treatment (0.1 mM)
(Figure 3C & D). This result suggests that TET enzymes,
though at a lower level than in healthy melanocytes, are
ready to generate 5hmC in melanoma cells but are waiting
for vitamin C to assist the hydroxylation reaction. Thus,
the accumulated vitamin C within the cells led to a time-
dependent increase of 5hmC. It is important to note that
the difference between the time points of 24 h and 48 h was
miniscule, which could in part be due to the fact that 5hmC
is not maintained during DNA replication in these rapidly
growing cells. These results once again indicate that vitamin
C at physiological levels partially reestablishes the content of
5hmC in melanoma cells, which is comparable to the effect
of overexpressing TET2 in the same cell line [3].
Vitamin C treatment inhibited the malignant phenotype
of melanoma cells
We then questioned what the functional consequences of
the vitamin C-increased 5hmC content could be in terms of
melanoma malignancy. According to our observation de-
scribed above, vitamin C at physiological concentrations is
able to restore the global content of 5hmC as efficiently as
to that of pharmacological concentrations in melanoma cells
in vitro. In that regard, we tested the effect of vitamin C at
physiological concentrations on behaviors of melanomaFigure 4 Vitamin C treatment decreases the malignant phenotype of A205
levels (0.5 mM to 2 mM) inhibits A2058 cell proliferation while it does not affe
(B) Treatment with vitamin C (0.1 mM) mitigates A2058 cell migration as teste
the anchorage-independent growth of A2058 cells, and 0.01 mM vitamin C h
in (C). Quantitative data of colonies formed (#/well) in the soft-agar assay (D).cells. In the cell proliferation analysis, we observed that
treatment with vitamin C at physiological concentrations
(0.05 mM to 0.1 mM) did not evidently affect the growth
rate of A2058 cells (Figure 4A) as well as healthy melano-
cytes (data not shown). In contrast, vitamin C at pharma-
cological concentrations (0.5 mM to 2 mM) significantly
inhibited not only A2058 cell proliferation (P < 0.05), but
also the cell growth rate of healthy melanocytes (data not
shown). Since such high concentrations (0.5 mM to
2 mM) of vitamin C treatment appeared to be toxic to
many types of non-malignant cells including healthy mela-
nocytes, pharmacological concentration of vitamin C
treatment might not be a practicable option for cancer
therapy. This might explain why vitamin C treatment at
pharmacological concentrations resulted in inconsistent
therapeutic results for cancer [20]. Overall, our results
suggest that vitamin C at physiological concentrations
does not affect cell proliferation of both melanoma
(A2058) cells and healthy melanocytes. It appears to be
safe for clinical application.
Interestingly, although vitamin C at physiological con-
centrations had little effect on cell proliferation of mel-
anoma (A2058) cells, it indeed altered melanoma cell
migration and in vitro transformation. In our experi-
ments using the transwell cell migration assay to evalu-
ate the effect of vitamin C treatment at physiological
concentrations on melanoma cell migration, we treated
A2058 cells with or without vitamin C (0.1 mM) for
24 h and tested their ability to migrate in the transwell.
We observed that vitamin C at a physiological level
(0.1 mM) significantly inhibited A2058 cell transwell mi-
gration (Figure 4B).8 cells in vitro. (A) MTT assay shows that Vitamin C at pharmacological
ct A2058 cell proliferation at physiological levels (0.05 mM to 0.1 mM).
d by the transwell assay. (C to D) Vitamin C treatment (0.1 mM) inhibits
as no obvious effect. A representative image of soft-agar assay is shown
(*P < 0.05).
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marks of transformation. It is considered the most ac-
curate and stringent in vitro assay to detect malignant
transformation of cells in vitro. We further examined
the effect of vitamin C treatment at physiological concen-
trations on anchorage-independent growth of melanoma
cells. We observed that supplementation of vitamin C
(0.1 mM) drastically inhibited A2058 cell colony forma-
tion in the soft agar, while 0.01 mM vitamin C did not ob-
viously affect the colony formation (Figures 4C & D). This
result suggests that vitamin C at a physiological level
(0.1 mM) mitigated malignant transformation of melan-
oma cells. Considered together, our results demonstrate
that vitamin C at physiological concentrations could sig-
nificantly reduce the malignant phenotype of A2058 cells
in vitro by inhibiting cell migration and transformation
but not suppressing cell proliferation. Hence, vitamin C at
physiological concentrations might be applied as a safe
and clinically sound therapeutic option.
Vitamin C treatment shifted the transcriptome of
melanoma cells
We examined the possible mechanisms that could reveal
how vitamin C suppresses cell migration and anchorage-
independent growth of A2058 cells. Vitamin C is a micro-
nutrient and has been proven to serve many different
functions, including anti-oxidation and acting as a cofac-
tor for a list of iron and 2-oxoglutarate-dependent dioxy-
genases. We and others have shown that the effect of
vitamin C on 5hmC generation is independent of its prop-
erty as a general reducer [13-17]. Of the known enzymes
requiring vitamin C as a cofactor, only TETs and its medi-
ated hydroxylation of 5mC to 5hmC have known direct
impacts on gene transcriptions. Thus, we hypothesizedFigure 5 Vitamin C treatment shifts the transcriptome of A2058 cells. After
are identified by EdgeR (1,147 genes), DEseq (789 genes), and Bayseq (74 g
of all three methods.that the vitamin C-induced global increase of 5hmC
could, at least in part, be responsible for the phenotypic
consequences of A2058 cells by changing gene expression
profiles.
To test our hypothesis, we conducted RNA-seq to
evaluate the influence of vitamin C treatment on the
transcriptome of A2058 cells. In order to minimize po-
tential secondary effects in the long term, A2058 cells
were treated with vitamin C at physiological concentra-
tions (0.1 mM) for 48 h. DNA and RNA were simultan-
eously extracted from A2058 cells cultured in the same
wells (n = 3 per group). After the vitamin C-induced
5hmC were confirmed by dot-blot assay (data not shown),
RNA were submitted to the Sequencing Core of John P.
Hussman Institute of Human Genomics at the University
of Miami. We applied rigorous bioinformatic and statis-
tical approaches to analyze the RNA-seq data. The results
showed that 1,147 genes were differentially expressed by
EdgeR, 789 genes by DEseq, and 74 genes by Bayseq, re-
spectively. However, only 66 genes including a few of non-
coding transcripts were significantly and differentially
expressed in the analyses of all three methods - EdgeR,
DESeq, and BaySeq (Figure 5). Of the 66 genes, seven genes
were down-regulated while the rest of the 59 genes were
up-regulated. Then, we chose the top ten genes for valid-
ation based on fold changes (≥1.6-fold increase or ≤0.7 fold
decrease) in multiple callers. The expression changes of all
ten genes had been verified by qRT-PCR (Table 1). How-
ever, the ten verified genes may not be able to fully explain
the effects of vitamin C on the altered malignant phenotype
of A2058 cells. The most significant change induced by
vitamin C treatment occurs in the gene rho GTPase activat-
ing protein 30 (ARHGAP30, ≥tenfold increase). Unfortu-
nately, western blot using different sources of antibody didvitamin C (0.1 mM) treatment for 48 h, differentially expressed genes
enes) analysis. However, only 66 genes are overlapped by the analyses
Table 1 Differentially expressed genes in A2058 cells used by vitamin C treatment
No Symbol Gene RNA-seq (DESeq) qRT-PCR
Fold P value Fold P value
1 ARGHAP30 Rho GTPase activating protein 30 15.2 4.73 × 10−21 10.3 2.2 × 10−5
2 TRIM63 Tripartite motif containing 63, E3 ubiquitin-protein ligase 5.3 2.15 × 10−05 4.3 2.2 × 10−5
3 PTPN7 Protein tyrosine phostaphatase, non-receptor type 7 3.8 0.01 2.6 8 × 10
4 SOCS3 Suppressor of cytokine signaling 3 1.9 1 × 10−4 2 9 × 10−3
5 FAP Fibroblast activation protein, alpha 1.7 3.43 × 10−21 1.6 0.01
6 GPRIN3 GPRIN family member 3 1.7 5 × 10−5 2 3 × 10−4
7 TIMP3 TIMP metallopeptidase inhibitor 3 1.6 5 × 10−5 1.5 0.01
8 MAGEA4 Melanoma antigen family A 1.6 5 × 10−5 1.8 1 × 10−4
9 SERPINE2 Serpin, peptidase inhibitaor clade E, member 2 0.67 2.5 × 10−4 0.79 0.01
10 SLITRK2 SLIT and NTRK-like family member 2) 0.49 1 × 10−4 0.66 2 × 10−3
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size. Nevertheless, we have decided to examine ARHGAP30
at protein level in future studies. By pathway enrichment
analysis, we found that the most prominent changes oc-
curred in the extracellular matrix (ECM)-remodeling path-
way including TIMP metallopeptidase inhibitor 3 (TIMP3)
and GPRIN family member 3 (GPRIN3). Changes in these
genes may explain, at least in part, the inhibitory effect
of vitamin C on A2058 cell migration and anchorage-
independent growth.Discussion
Recent discoveries of the epigenetic abnormalities in
cancer provide unprecedented opportunities to repro-
gram malignant cancer cells and alter them toward
healthy cells by targeting related enzymes that are re-
sponsible for the epigenetic modifications [21]. The con-
version of 5mC to 5hmC requires a catalytic complex
that is at least composed of the TET enzymes, the co-
substrate 2-oxoglutarate, and the cofactor Fe2+. We, for
the first time, reported that vitamin C is an additional
cofactor for TETs to generate 5hmC. This was subse-
quently verified by three other groups and is now widely
accepted [13-17]. Interestingly, the loss of 5hmC has
been identified as a novel hallmark for most, if not all,
types of cancer [1-4]. Various mechanisms may underlie
5hmC depletion in cancer such as mutations in TETs
and IDHs [1,22] and thus decreased expression of TETs
and IDHs [3]. Published studies have shown that overex-
pressing TET2 in melanoma cells and TET1 in breast
cancer cells increases their 5hmC content and decreases
their malignancy in vitro and in vivo [3,23]. However, it
might not be feasible to overexpress TETs in cancer pa-
tients as a therapeutic option. This study attempted to
identify alternative means that may rebuild the 5hmC
content in malignant cells as a potential treatment for
cancer.Contrary to what one might expect, more than 7% of
the US population (>20 million individuals) is estimated
to be deficient in vitamin C (concentrations <11.4 μM in
plasma) [24,25]. Further, the turnover rate of vitamin C
appears quite rapid, suggesting that the number of
people with short-term vitamin C deficiency could be
even higher [26]. Possibly due to the fact that it is nearly
impossible to quantitatively control dietary vitamin C
consumption in human subjects, an epidemiological link
between vitamin C deficiency and the incidence of mel-
anoma has yet been published.
Interestingly, recurrent mutations in the splicing factor
SF3B1 have been identified in certain types of melanoma
[27]. The mutant SF3B1 causes a truncated, most likely
nonfunctional, SVCT2 that can result in intracellular de-
ficiency of vitamin C in cancer cells [28]. Besides a lower
expression of TETs in melanoma cells as verified in this
research, we also found that the expression of SVCTs
was also significantly decreased especially in metastatic
melanoma cell lines. This result suggests that a local de-
ficiency of vitamin C, due to less transporters in meta-
static melanoma cells, could also be responsible for the
loss of 5hmC in metastatic melanoma.
Based on the recent findings, including ours, [13-17]
we sought to test whether vitamin C could be an alter-
native of TETs overexpression to restore 5hmC in cul-
tured melanoma cells. Distinct from previous studies of
using pharmacological concentrations, we chose vitamin
C at physiological concentrations, which can be conveni-
ently reached by diet and dietary supplements, to treat
cells. We showed that vitamin C treatment indeed rees-
tablished 5hmC global content toward that in healthy
melanocytes. Interestingly, higher concentration of vita-
min C did not cause an even higher level of 5hmC in
melanoma cells, indicating that vitamin C at physio-
logical levels can satisfy the need of TETs, though at low
expression level, and maximize their enzymatic activity
to generate 5hmC in melanoma cells.
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at physiological concentrations also caused phenotypic
changes in cultured melanoma cells. In vitro assays
showed that vitamin C (0.1 mM) treatment decreased the
malignant phenotype of A2058 cells by inhibiting cell mi-
gration and anchorage-independent growth, while exerting
no obvious effect on proliferation rate. Published studies
have shown that vitamin C depletion increases the growth
and metastasis of melanoma cells in L-gulonolactone
oxidase-knockout (Gulo−/−) mice that mimic the human
inability to synthesize ascorbate [29]. Further, supplemen-
tation of vitamin C could inhibit the growth and metasta-
sis of melanoma cells in Gulo−/− mice [30]. These results
suggest that vitamin C treatment could decrease the ma-
lignant phenotype of melanoma in vitro and in vivo.
Consistent with the dual function of TETs and the
consequent 5hmC on transcription regulation [31], vita-
min C-induced 5hmC also correlated with bi-directional
effects on transcription, although the most significantly
altered transcripts were up-regulated. An ideal study will
be an integrated analysis of RNA-seq and sequencing
5hmC in the genome of melanoma cells after vitamin C
treatment. However, due to limits in financial support, a
detailed 5hmC profiling by high-throughput sequencing
can only be conducted in the future. Nevertheless, this
research has successfully captured the most significant
genes sensitive to vitamin C treatment in A2058 cells.
The most predominant change occurs in the ARH-
GAP30 gene, of which the expression is increased more
than tenfold after vitamin C treatment. Interestingly, not
so much is known about the function of this gene. How-
ever, a recent report showed that ARHGAP30 is required
for acetylation and functional activation in colorectal can-
cer. A low level of ARHGAP30 expression also is associ-
ated with poor survival of CRC patients [32]. A dramatic
increase in ARHGAP30 expression caused by vitamin C
can enhance the tumor suppressor activity of p53, further
decreasing the malignancy. Thus, this study primarily
links vitamin C to P53 in cancer treatment.
Furthermore, ECM remodeling appeared to be the pri-
mary pathway regulated by vitamin C. Other than GPRIN3,
the most notable gene in this pathway is TIMP metallo-
peptidase inhibitor 3 (TIMP-3). Interestingly, overexpress-
ing TET1 has been shown to activate TIMPs expression in
breast cancer cells [23]. The mechanisms of how these al-
tered genes contribute to the decreased malignancy of
A2058 cells remain unclear and require further examin-
ation in the future.
Astonishingly, vitamin C is often absent in the formu-
lation of the majority of media used for culturing cancer
cells [33]. This suggests that the critical regulatory role of
vitamin C in the cancer epigenome might have been over-
looked in previous cell-based studies. On the other hand,
immunocompromised or genetically modified mice havebeen overwhelmingly used in cancer research. However,
unlike humans, mice can synthesize vitamin C de novo.
This implicates that previous mice-based studies might
have ignored the effect of variation in vitamin C availabil-
ity on the cancer epigenome.
In addition to restoring 5hmC in melanoma cells as
described above, vitamin C at pharmacological doses
also have been shown to inhibit the activity of DNA
methyltransferases and to alter the expression of many
miRNAs [34]. Besides these epigenetic pathways, the
toxicity of vitamin C at mM ranges is also through react-
ive oxygen species pathways [35]. Taken together, vita-
min C, a safe and well-tolerated micronutrient, needs to
be further evaluated in melanoma treatment.
Conclusions
Our study demonstrates that treatment of vitamin C at a
physiological concentration can decrease the malignant
phenotype of melanoma cells in vitro by partially reestab-
lishing the global content of 5hmC and the consequent al-
teration in the transcriptome. These results suggest that
vitamin C could be a potential epigenetic treatment for
melanoma and perhaps other types of cancer.
Methods
Cell culture and treatments
Melanocyte line (FOM-113), derived from a healthy hu-
man subject, and melanoma cell lines derived from ra-
dial growth phase (RGP, SBcl2 and WM35) and vertical
growth phase (VGP, WM278 and WM3248) as well as
metastatic phase (C8161) were gifts from Dr. M. Herlyn
(The Wistar Institute). Another line of metastatic melan-
oma (A2058) was purchased from ATCC. Cells were cul-
tured in the media as described [33]. The media used to
maintain these cell lines did not contain any vitamin C
in their formulas. After seeding in 6-well plates for 24 h,
cells were treated with vitamin C (L-ascorbic acid,
Sigma-Aldrich, St Louis, MO, USA) at different concen-
trations for varying durations. Each treatment group
consisted of three wells for every experiment. Each ex-
periment was repeated at least three times.
Quantitative real-time RT-PCR
RNA was extracted from cultured melanocytes and vari-
ous melanoma cells using RNeasy kits (Qiagen, Hilden
Germany). A nanodrop 8000 photospectrometer was used
to measure the yield of RNA extraction. The SuperScript
III First-Strand Synthesis System (Invitrogen, Carlsbad,
CA, USA) was used for reverse transcription (RT) accord-
ing to the manufacturer’s instructions. Quantitative real-
time RT-PCR (qRT-PCR) was performed in triplicate on a
Roche LightCycler 480. The 10-μl reaction contains SYBR
Green master mix, primers, and diluted cDNA (100 ng).
All primers were designed to span introns (Table 2). The
Table 2 Primers for quantitative real-time RT-PCR
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LightCycler 480 software, and all values were normalized
to the levels of the GAPDH using the 2-(ΔΔCt) method.
Statistical significance of differences in expression levels
between melanocytes and different melanoma cell lines or
between A2058 cells treated with or without vitamin C
were assessed by Student t test, at α = 0.05.Dot-blot assay
Genomic DNA was extracted from cultured melanocytes
and various melanoma cells using QIAamp DNA mini
kits (Qiagen, Hilden Germany) according to the manu-
facturer’s instructions. A Qubit Fluorometer (Life Tech-
nology, Foster City, CA, USA) was used to quantify the
concentration of DNA. The dot-blot procedure followed
the published methods as conducted in our previous
studies [13]. Briefly, DNA samples were diluted with 2 N
NaOH and 10 mM Tris · Cl and pH 8.5 then loaded on a
Hybond N+ nylon membrane (GE Health, Piscataway,
NJ, USA) using a 96-well dot-blot apparatus (Bio-Rad,
Richmond, CA, USA). After baking at 80°C for 30 min
and being blocked by 5% non-fat milk for 1 h at room
temperature, the membrane was incubated in a poly-
clonal anti-5hmC antibody (Active Motif, Carlsbad, CA,
USA; #39769, 1:10,000) at 4°C overnight. 5hmC was visu-
alized by chemiluminescence. The densities of the dots
were captured by AlphaImager. To ensure equal loading,
the membrane was stained with methylene blue post-
immunoblotting. Statistical significance of differences in
5hmC content between different treatments were assessed
by Student t test at α = 0.05.MTT assay
Cell growth was measured using MTT cell proliferation
kits (BioVision Technologies, Exton, PA, USA) according
to the manufacturer’s instruction. Briefly, 5 × 103 cells/well
were cultured in 96-well plates and cultured in the
medium supplemented with or without vitamin C as indi-
cated in individual experiments. Samples were assayed in
six replicates and these experiments were repeated three
times.
Cell migration assay
Tumor cell migration was tested in transwell using BD
Falcon FluoroBlok™ Systems with an 8-μm porous mem-
brane insert (BD Biosciences, San Jose, CA, USA). A
total of 1 × 104 A2058 melanoma cells were suspended
in a 0.3-mL serum-free medium and seeded in 8-μm
pore Fluoroblok inserts and left to migrate toward the
lower chamber containing 0.7 mL of tumor medium
with 1% FBS. Wells were divided into two groups (three
wells/group) as follows: vitamin C (+) and vitamin C (−)
groups. In the vitamin C (+) group, vitamin C (0.1 mM)
was supplemented in both the insert and the low cham-
ber. Cells were cultured at 37°C for 16 h. Migrated cells
were counted using an Olympus TH4-100 fluorescence
microscope connected to a DP-70 Olympus digital cam-
era (Olympus, Tokyo, Japan).
Colony formation assay
Tumor cell colony formation in soft agar was carried out
as described [36]. Briefly, 3 × 10 A2058 melanoma cells
per well were embedded into 0.33% agar gel containing
FBS in 6-well plates pre-coated with 0.5% of agar solution
Gustafson et al. Clinical Epigenetics  (2015) 7:51 Page 10 of 11in triplicate and covered with tumor medium supple-
mented with or without vitamin C (0.01 or 0.1 mM) or as
indicated in the individual experiment. Medium was re-
placed every other day. Colonies (defined as a minimum
of four cells) were counted after 15 days of incubation.
RNA-seq
A2058 cells cultured in 6-well plates were treated with or
without vitamin C (0.1 mM) for 48 h. Medium was chan-
ged daily before each treatment to avoid the accumulation
of vitamin C in the medium. Total RNA was then ex-
tracted from these cells. A Bioanalyzer 2000 (Agilent, Palo
Alto, CA, USA) was used to monitor the quality of RNA.
All samples’ RNA integrity numbers (RIN) were above nine
(data not shown). The whole transcriptome sequencing was
carried out at the Sequencing Core of John P. Hussman
Institute of Human Genomics at the University of
Miami. Briefly, after ribosome RNA (rRNA) was de-
pleted, sequencing libraries were constructed following
the standard Illumina protocols and were subsequently
processed by a Hiseq2500 (Illumina, San Diego, CA, USA)
sequencing system (200 bp paired-end reads, four samples
per lane). Raw read data was first run through quality con-
trol metrics using FastQC (http: //www.bioinformatics.bab
raham.ac.uk/projects/fastqc/). After quality control was
checked, sequence reads were aligned using the STAR
aligner [37]. The aligned reads from the STAR aligner was
then run through HTseq for transcript quantification
against the GENCODE v19.gtf file [38]. After all features
were quantified, the data was then run through three dif-
ferent differential expression calculators in EdgeR, DESeq,
and BaySeq [39-41]. The intersection of the three methods
were taken and transformed into a list of the final differen-
tially expressed features. Differentially expressed features
were determined by cutoff adjusted P values of 0.05 across
all three methods. That final list was then put through gene
ontology annotation using the BiNGO added into Cytos-
cape v 3.1.1 [42]. The list was also run through GeneGO
for pathway enrichment (https://www.portal.genego.com).
Statistical analysis
All data were normalized by inner controls, such as GAPDH
expression level. Data was presented as mean ± SD. Statis-
tically significant changes among treatments were
assessed by Student t tests at α = 0.05.
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